Bone Biologics CEO Jeff Frelick joins Natalie Stoberman from the Proactive studios to discuss the latest progress in its pilot clinical trial for the NB1 bone graft device.
Bone Biologics was founded to pursue regenerative medicine for bone. The company is undertaking preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.